Global GLP-1 Market Strategic Intelligence Suite 2026-2031

Publication ID:

NAV0826022

Publication Date:

August 26, 2026

Countries:

Global [1]

The Global GLP-1 Market Strategic Intelligence Suite 2026–2031 comprises two full-length strategic research reports viewed together for the first time - the Global GLP-1 Drug Market Report (demand-side) and the Global GLP-1 Drug Manufacturing & Supply Chain Market Report (supply-side) - plus this summary and accompanying presentation and infographic.

GLP-1 drugs (used for both type 2 diabetes and obesity/weight management) represent one of the fastest-growing and most capacity-constrained categories in global pharmaceuticals. This suite covers both the demand side (drug market revenue, product-level competitive dynamics, indication mix) and the supply side (manufacturing capacity, peptide synthesis, CDMO landscape) in a single integrated resource.

The Global GLP-1 Drug Market Report [2] (demand-side) was valued at $70.58 billion in 2025 and is projected to reach $145.39 billion by 2031, a CAGR of 12.8%. The report's single most consequential finding is a real, ongoing competitive leadership reversal: Eli Lilly's tirzepatide franchise overtook Novo Nordisk's semaglutide franchise for US market leadership during 2025, reaching an estimated 57% US market share, with Eli Lilly's market capitalisation crossing $1 trillion in August 2026 - the first healthcare company in history to do so.

The Global GLP-1 Drug Manufacturing & Supply Chain Market Report [3] (supply-side) was valued at $45.0 billion in 2025 and is projected to reach $180.0 billion by 2031, a CAGR of 26.0% - roughly double the demand-side rate. Both Eli Lilly and Novo Nordisk have publicly confirmed manufacturing capacity, not demand, as the binding constraint on patient access, and a real, quantified reshoring wave is underway: of $24.86 billion in total 2025 CDMO capacity investment, approximately 74% ($18.48 billion) was directed to US and non-China facilities.

2. The Core Finding: A Capacity-Constrained Market

The GLP-1 category shows one of the widest demand/supply growth-rate divergences of any pharmaceutical sub-sector currently tracked - manufacturing capacity value is forecast to overtake drug-market revenue by 2031. Three structural factors explain this: peptide synthesis complexity requiring years of fermentation-capacity build-out, dual-indication demand (diabetes + obesity) compounding volume faster than any comparable recent drug class, and strategic multi-billion-dollar capacity investment specifically targeting the demand-supply gap.

Suite Components

Component	Content
Report 1: Drug Market	Drug revenue, product-level competitive dynamics (tirzepatide/semaglutide), indication split, regional forecasts
Report 2: Manufacturing & Supply Chain	Manufacturing capacity, peptide/fermentation production, CDMO landscape, reshoring investment
Executive Presentation	12-slide integrated comparative presentation
Summary Document (DOCX)	Integrated executive summary of both reports' headline and deep findings
Interactive Infographic (HTML)	Visual one-page infographic for digital distribution

Please Note: individual reports can also be purchased separately based on your specific data needs.

Global GLP-1 Market Strategic Intelligence Suite — Overview
1. Suite Introduction: The Global GLP-1 Value Chain 2026–2031
2. How the Two Reports Interconnect: Manufacturing Capacity vs. Drug Market Revenue
3. Suite Bonus Deliverables: Executive Presentation, Summary Document, and Infographic
Report 1: Global GLP-1 Drug Market Strategic Research Report 2026–2031 (Demand-Side)
Executive Summary
1. 1.1 Market Positioning Statement
2. 1.2 Market Sizing and Forecast Overview
3. 1.3 The Competitive Landscape: A Leadership Reversal in Real Time
4. 1.4 Market Segmentation Overview
5. 1.5 Primary Growth Drivers and Inhibitors
6. 1.6 Strategic Implications
Industry Overview & Forecast
1. 2.1 Market Scale and Historical Trajectory
2. 2.2 Forecast Structure and Growth Rate Assumptions
3. 2.3 Market Segmentation by Product Type
4. 2.4 Market Segmentation by Application
5. 2.5 Regional Market Dynamics
6. 2.6 Transition from Early-Launch to Maturity Phase
Market Segmentation by Type
1. 3.1 Overview and Segment Architecture
2. 3.2 Tirzepatide (Mounjaro/Zepbound)
3. 3.3 Semaglutide Injectable (Ozempic/Wegovy)
4. 3.4 Oral Semaglutide (Rybelsus)
5. 3.5 GLP-1 Biosimilars and Emerging Pipeline
6. 3.6 Dulaglutide (Trulicity) — Legacy Segment in Structural Decline
7. 3.7 Segment Synthesis and Competitive Positioning
Market Segmentation by Application
1. 4.1 Application Landscape Overview
2. 4.2 Type 2 Diabetes
3. 4.3 Obesity and Weight Management
4. 4.4 Cardiovascular Risk Reduction
5. 4.5 Chronic Kidney Disease
6. 4.6 Other Emerging Applications
7. 4.7 Application Segmentation
Regional Market Forecast
1. 5.1 North America
2. 5.2 Europe
3. 5.3 Asia Pacific
4. 5.4 Latin America
5. 5.5 MEA
Country-Level Market Forecast
1. 6.1 North America
2. 6.1.1 United States
3. 6.1.2 Canada
4. 6.2 Europe
5. 6.2.1 Germany
6. 6.2.2 United Kingdom
7. 6.2.3 France
8. 6.2.4 Italy
9. 6.2.5 Spain
10. 6.2.6 Rest of Europe
11. 6.3 Asia Pacific
12. 6.3.1 Japan
13. 6.3.2 China
14. 6.3.3 South Korea
15. 6.3.4 India
16. 6.3.5 Australia
17. 6.3.6 Rest of Asia Pacific
18. 6.4 Latin America
19. 6.4.1 Brazil
20. 6.4.2 Mexico
21. 6.4.3 Argentina
22. 6.4.4 Colombia
23. 6.4.5 Rest of Latin America
24. 6.5 MEA
25. 6.5.1 Saudi Arabia
26. 6.5.2 United Arab Emirates
27. 6.5.3 South Africa
28. 6.5.4 Turkey
29. 6.5.5 Rest of MEA
Growth Drivers & Inhibitors
1. 7.1 Overview
2. 7.2 Primary Growth Drivers
3. 7.2.1 Accelerating Indication Expansion Beyond Core Metabolic Disease
4. 7.2.2 Oral Formulation Development Structurally Expanding the Addressable Patient Population
5. 7.2.3 Manufacturing Capacity Expansion Resolving Structural Supply Constraints
6. 7.3 Primary Market Inhibitors
7. 7.3.1 US Government Pricing Interventions Compressing Per-Unit Revenue
8. 7.3.2 Medicare Part D Negotiated Pricing Introducing Sustained Structural Pricing Pressure
9. 7.3.3 Compounded and Unauthorised GLP-1 Products Eroding Cash-Pay Revenue
10. 7.3.4 Biosimilar and Generic Entry Compressing Average Selling Prices Across the Category
11. 7.4 Net Assessment
12. Global GLP-1 Drug Market Strategic Research Report 2026-2031
Key Company Profiles
1. 8.1 Eli Lilly and Company
2. 8.1.1 Company Overview
3. 8.1.2 Key Products & Segments
4. 8.1.3 Financial Performance (2023–2025)
5. 8.1.4 Business Strategy
6. 8.1.5 SWOT Analysis
7. 8.1.6 Strategic Implications (2025–2031)
8. 8.2 Novo Nordisk A/S
9. 8.2.1 Company Overview
10. 8.2.2 Key Products & Segments
11. 8.2.3 Financial Performance (2023–2025)
12. 8.2.4 Business Strategy
13. 8.2.5 SWOT Analysis
14. 8.2.6 Strategic Implications (2025–2031)
15. 8.3 Biocon Biologics Limited
16. 8.3.1 Company Overview
17. 8.3.2 Key Products & Segments
18. 8.3.3 Financial Performance (2023–2025)
19. 8.3.4 Business Strategy
20. 8.3.5 SWOT Analysis
21. 8.3.6 Strategic Implications (2025–2031)
22. 8.4 Amgen Inc.
23. 8.4.1 Company Overview
24. 8.4.2 Key Products & Segments
25. 8.4.3 Financial Performance (2023–2025)
26. 8.4.4 Business Strategy
27. 8.4.5 SWOT Analysis
28. 8.4.6 Strategic Implications (2025–2031)
29. 8.5 Viking Therapeutics
30. 8.5.1 Company Overview
31. 8.5.2 Key Products & Segments
32. 8.5.3 Financial Performance (2023–2025)
33. 8.5.4 Business Strategy
34. 8.5.5 SWOT Analysis
35. 8.5.6 Strategic Implications (2025–2031)
36. 8.6 Zealand Pharma A/S
37. 8.6.1 Company Overview
38. 8.6.2 Key Products & Segments
39. 8.6.3 Financial Performance (2023–2025)
40. 8.6.4 Business Strategy
41. 8.6.5 SWOT Analysis
42. 8.6.6 Strategic Implications (2025–2031)
43. 8.7 Hanmi Pharmaceutical Co.
44. 8.7.1 Company Overview
45. 8.7.2 Key Products & Segments
46. 8.7.3 Financial Performance (2023–2025)
47. 8.7.4 Business Strategy
48. 8.7.5 SWOT Analysis
49. 8.7.6 Strategic Implications (2025–2031)
50. 8.8 Roche / Genentech
51. 8.8.1 Company Overview
52. 8.8.2 Key Products & Segments
53. 8.8.3 Financial Performance (2023–2025)
54. 8.8.4 Business Strategy
55. Global GLP-1 Drug Market Strategic Research Report 2026-2031
56. 8.8.5 SWOT Analysis
57. 8.8.6 Strategic Implications (2025–2031)
Competitive Landscape
1. 9.1 Competitive Landscape Overview
2. 9.2 Competitive Intensity Assessment
3. 9.2.1 Tier Structure and Revenue Ranges
4. 9.2.2 Capacity vs. Demand Dynamics
5. 9.2.3 Pricing Environment
6. 9.2.4 Barriers to Entry and Exit
7. 9.3 Key Player Strategies & Positioning
8. 9.4 Competitive Dynamics & Strategic Outlook
9. 9.4.1 The Duopoly Under Siege
10. 9.4.2 Competitive Threat Matrix: Entrant Profiles and Entry Timelines
11. 9.4.3 Emerging Competitive Threats: Three Distinct Vectors
12. 9.4.4 Consolidation Versus Fragmentation Outlook
13. 9.4.5 Strategic Recommendations: 2025–2031
Porter's Five Forces Analysis
1. 10.1 Threat of New Entrants
2. 10.2 Bargaining Power of Buyers
3. 10.3 Bargaining Power of Suppliers
4. 10.4 Threat of Substitutes
5. 10.5 Competitive Rivalry
PESTLE Analysis
1. 11.1 Overview
2. 11.2 Political
3. 11.2.1 Government Drug Pricing Intervention
4. 11.2.2 Medicare Part D Negotiated Pricing
5. 11.2.3 International Affordability and Access Policy
6. 11.2.4 Political Risk in Emerging Markets
7. 11.2.5 Summary Assessment
8. 11.3 Economic
9. 11.3.1 Market Scale and Growth Trajectory
10. 11.3.2 Affordability and Payer Economics
11. 11.3.3 Price Reduction and Volume Dynamics
12. 11.3.4 Currency Dynamics and Novo Nordisk Exposure
13. 11.3.5 R&D Investment Economics
14. 11.3.6 Biosimilar Economics
15. 11.3.7 Macroeconomic Sensitivity
16. 11.4 Societal
17. 11.4.1 Global Obesity Epidemic as Structural Demand Driver
18. 11.4.2 Stigma Reduction and Patient Empowerment
19. 11.4.3 Health Equity and Access Disparities
20. 11.4.4 Shifting Perceptions of Weight Loss Treatment
21. 11.4.5 Ageing Demographics
22. 11.4.6 Physician Prescribing Culture
23. 11.5 Technological
24. 11.5.1 Tirzepatide's Dual-Agonist Innovation
25. 11.5.2 Oral GLP-1 Formulation Development
26. 11.5.3 Triple and Multi-Receptor Agonist Development
27. 11.5.4 Manufacturing Technology and Capacity
28. 11.5.5 Delivery Technology Innovation
29. 11.5.6 AI and Digital Health Integration
30. 11.5.7 Biosimilar Technology Complexity
31. Global GLP-1 Drug Market Strategic Research Report 2026-2031
32. 11.6 Legal
33. 11.6.1 Intellectual Property Landscape
34. 11.6.2 Patent Litigation
35. 11.6.3 Regulatory Approval and Label Expansion Litigation
36. 11.6.4 Product Liability
37. 11.6.5 Antitrust and Competition Law
38. 11.6.6 Data Privacy in Digital Health Integration
39. 11.7 Environmental
40. 11.7.1 Manufacturing Carbon Footprint
41. 11.7.2 Pharmaceutical Waste and Environmental Contamination
42. 11.7.3 Climate Resilience of Supply Chains
43. 11.7.4 Packaging and Cold Chain Sustainability
44. 11.7.5 Environmental Drivers of Chronic Disease
45. 11.7.6 ESG-Linked Capital Allocation
46. 11.8 PESTLE Synthesis and Strategic Implications
SWOT Analysis
1. 12.1 Strategic Framework Overview
2. 12.2 Strengths
3. 12.2.1 Validated, Expanding Clinical Efficacy Profile
4. 12.2.2 Incumbent Commercial Infrastructure at Scale
5. 12.2.3 Manufacturing Scale as a Structural Moat
6. 12.2.4 Category-Level Brand Recognition and Patient Pull
7. 12.3 Weaknesses
8. 12.3.1 Pricing Vulnerability and Reimbursement Dependency
9. 12.3.2 Manufacturing Complexity and Yield Constraints
10. 12.3.3 Patient Discontinuation and Adherence Dynamics
11. 12.3.4 Duopoly Concentration Risk
12. 12.4 Opportunities
13. 12.4.1 Indication Expansion Across Metabolic and Cardiometabolic Disease
14. 12.4.2 Oral Formulation Development and Route Diversification
15. 12.4.3 Emerging Market Penetration
16. 12.4.4 Combination Therapy and Precision Medicine Positioning
17. 12.4.5 Digital Health and Adherence Platform Integration
18. 12.5 Threats
19. 12.5.1 Biosimilar and Generic Entry Pressure
20. 12.5.2 Regulatory and Policy Pricing Intervention
21. 12.5.3 Pipeline Competitive Entry from Well-Capitalised Challengers
22. 12.5.4 Safety Signal Risk and Pharmacovigilance Exposure
23. 12.5.5 Compounding and Unauthorised Substitution
24. 12.6 SWOT Synthesis and Strategic Implications
Future Trends & Outlook
1. 13.1 Executive Summary of the Outlook
2. 13.2 Pricing Reform and Policy Headwinds
3. 13.3 Indication Expansion: The Platform Medicine Transformation
4. 13.4 The Oral GLP-1 Revolution: Format Disruption and Access Expansion
5. 13.5 Biosimilar and Competitive Entry
6. 13.6 Regional Outlook
7. 13.7 Technology and Delivery Innovation: The Next Competitive Frontier
8. 13.8 Competitive Strategy Implications: Eli Lilly versus Novo Nordisk
9. 13.9 Key Risks and Scenarios to the Forecast
10. 13.10 Strategic Conclusions for Market Participants
Report 2: Global GLP-1 Drug Manufacturing & Supply Chain Market Strategic Research Report 2026–2031 (Supply-Side)
Executive Summary
1. 1.1 Market Sizing and Forecast Overview
2. 1.2 Important Methodological Note: Cross-Report Reconciliation
3. 1.3 Manufacturing Value Chain Segmentation
4. 1.4 Regional Manufacturing Distribution
5. 1.5 Principal Growth Drivers
6. 1.6 Principal Market Inhibitors
7. 1.7 Competitive Landscape Overview
8. 1.8 Strategic Conclusions
Industry Overview & Forecast
1. 2.1 Market Scale and Historical Trajectory
2. 2.2 Methodology Note and Cross-Report Reconciliation Flag
3. 2.3 Forecast: 2026–2031 Outlook
4. 2.4 Value Chain Segmentation
5. 2.5 Regional Distribution and Growth Dynamics
6. 2.6 Summary Assessment
Market Segmentation by Type
1. 3.1 Overview of the GLP-1 Manufacturing Value Chain
2. 3.2 Drug Product Formulation and Fill-Finish
3. 3.3 Delivery Device Manufacturing
4. 3.4 GLP-1 API Peptide Synthesis (CDMO)
5. 3.5 Primary Packaging and Containment
6. 3.6 Cold Chain and Temperature-Controlled Logistics
7. 3.7 Testing, Quality Control, and Regulatory Services
8. 3.8 Comparative Segment Summary and Share Dynamics
Market Segmentation by Application
1. 4.1 Overview of the GLP-1 Manufacturing Value Chain
2. 4.2 Segment 1: GLP-1 API Peptide Synthesis (CDMO)
3. 4.2.1 Segment Definition and Scope
4. 4.2.2 Market Size and Growth Trajectory
5. 4.2.3 Competitive Landscape and Capacity Dynamics
6. 4.2.4 Strategic Trends and Forward-Looking Analysis
7. 4.3 Segment 2: Drug Product Formulation and Fill-Finish
8. 4.3.1 Segment Definition and Scope
9. 4.3.2 Market Size and Growth Trajectory
10. 4.3.3 Competitive Landscape and Capacity Dynamics
11. 4.3.4 Strategic Trends and Forward-Looking Analysis
12. 4.4 Segment 3: Delivery Device Manufacturing
13. 4.4.1 Segment Definition and Scope
14. 4.4.2 Market Size and Growth Trajectory
15. 4.4.3 Competitive Landscape and Capacity Dynamics
16. 4.4.4 Strategic Trends and Forward-Looking Analysis
17. 4.5 Segment 4: Primary Packaging and Containment
18. 4.5.1 Segment Definition and Scope
19. 4.5.2 Market Size and Growth Trajectory
20. 4.5.3 Competitive Landscape and Capacity Dynamics
21. 4.5.4 Strategic Trends and Forward-Looking Analysis
22. 4.6 Segment 5: Cold Chain and Temperature-Controlled Logistics
23. 4.6.1 Segment Definition and Scope
24. Global GLP-1 Drug Manufacturing & Supply Chain Market Strategic Research Report 2026-2031
25. 4.6.2 Market Size and Growth Trajectory
26. 4.6.3 Competitive Landscape and Capacity Dynamics
27. 4.6.4 Strategic Trends and Forward-Looking Analysis
28. 4.7 Segment 6: Testing, Quality Control, and Regulatory Services
29. 4.7.1 Segment Definition and Scope
30. 4.7.2 Market Size and Growth Trajectory
31. 4.7.3 Competitive Landscape and Capacity Dynamics
32. 4.7.4 Strategic Trends and Forward-Looking Analysis
33. 4.8 Cross-Segment Integration and Strategic Observations
34. 4.8.1 Value Chain Concentration and Bottleneck Analysis
35. 4.8.2 Segment Share Evolution Through 2031
36. 4.8.3 Capital Investment Signals and their Segmental Implications
Regional Market Forecast
1. 5.1 North America
2. 5.2 Europe
3. 5.3 Asia Pacific
4. 5.4 Middle East & Africa
5. 5.5 Latin America
Country-Level Market Forecast
1. 6.1 North America
2. 6.1.1 United States
3. 6.1.2 Puerto Rico (US)
4. 6.1.3 Canada
5. 6.2 Europe
6. 6.2.1 Ireland
7. 6.2.2 Switzerland
8. 6.2.3 Germany
9. 6.2.4 Denmark
10. 6.2.5 Belgium
11. 6.2.6 Rest of Europe
12. Global GLP-1 Drug Manufacturing & Supply Chain Market Strategic Research Report 2026-2031
13. 6.3 Asia Pacific
14. 6.3.1 South Korea
15. 6.3.2 China
16. 6.3.3 India
17. 6.3.4 Japan
18. 6.3.5 Rest of Asia Pacific
19. 6.4 Middle East & Africa
20. 6.4.1 Saudi Arabia
21. 6.4.2 United Arab Emirates
22. 6.4.3 South Africa
23. 6.4.4 Egypt
24. 6.4.5 Rest of MEA
25. 6.5 Latin America
26. 6.5.1 Brazil
27. 6.5.2 Mexico
28. 6.5.3 Argentina
29. 6.5.4 Colombia
30. 6.5.5 Rest of LatAm
Growth Drivers & Inhibitors
1. 7.1 Overview
2. 7.2 Growth Drivers
3. 7.2.1 Manufacturer-Confirmed Capacity Constraint as the Primary Demand Limiter
4. 7.2.2 Quantified Reshoring-Driven Capital Investment Wave
5. 7.2.3 Indication Expansion Systematically Broadening the Addressable Patient Population
6. 7.3 Market Inhibitors
7. 7.3.1 Multi-Year Capital Lead Times Creating Demand-Supply Mismatch Risk
8. 7.3.2 Geopolitical and Export-Control Disruption to Chinese CDMO Capacity
9. 7.4 Composite Driver-Inhibitor Assessment
Key Company Profiles
1. 8.1 Eli Lilly and Company
2. 8.1.1 Company Overview
3. 8.1.2 Key Products & Segments
4. 8.1.3 Financial Performance (2023–2025)
5. 8.1.4 Business Strategy
6. 8.1.5 SWOT Analysis
7. 8.1.6 Strategic Implications (2025–2031)
8. 8.2 Novo Nordisk A/S
9. 8.2.1 Company Overview
10. 8.2.2 Key Products & Segments
11. 8.2.3 Financial Performance (2023–2025)
12. 8.2.4 Business Strategy
13. 8.2.5 SWOT Analysis
14. 8.2.6 Strategic Implications (2025–2031)
15. 8.3 Novo Holdings (via Catalent)
16. 8.3.1 Company Overview
17. 8.3.2 Key Products & Segments
18. 8.3.3 Financial Performance (2023–2025)
19. 8.3.4 Business Strategy
20. 8.3.5 SWOT Analysis
21. 8.3.6 Strategic Implications (2025–2031)
22. 8.4 Samsung Biologics
23. 8.4.1 Company Overview
24. 8.4.2 Key Products & Segments
25. 8.4.3 Financial Performance (2023–2025)
26. 8.4.4 Business Strategy
27. Global GLP-1 Drug Manufacturing & Supply Chain Market Strategic Research Report 2026-2031
28. 8.4.5 SWOT Analysis
29. 8.4.6 Strategic Implications (2025–2031)
30. 8.5 Lonza
31. 8.5.1 Company Overview
32. 8.5.2 Key Products & Segments
33. 8.5.3 Financial Performance (2023–2025)
34. 8.5.4 Business Strategy
35. 8.5.5 SWOT Analysis
36. 8.5.6 Strategic Implications (2025–2031)
37. 8.6 WuXi Biologics
38. 8.6.1 Company Overview
39. 8.6.2 Key Products & Segments
40. 8.6.3 Financial Performance (2023–2025)
41. 8.6.4 Business Strategy
42. 8.6.5 SWOT Analysis
43. 8.6.6 Strategic Implications (2025–2031)
44. 8.7 Biocon Biologics
45. 8.7.1 Company Overview
46. 8.7.2 Key Products & Segments
47. 8.7.3 Financial Performance (2023–2025)
48. 8.7.4 Business Strategy
49. 8.7.5 SWOT Analysis
50. 8.7.6 Strategic Implications (2025–2031)
Competitive Landscape
1. 9.1 Competitive Landscape Overview
2. 9.1.1 Market Structure and Concentration
3. 9.1.2 Estimated Market Share by Leading Player (2025)
4. 9.1.3 Herfindahl-Hirschman Index and Concentration Assessment
5. 9.1.4 Overall Competitive Intensity Rating: Low to Moderate
6. 9.2 Competitive Intensity Assessment
7. 9.2.1 Tier Classification and Revenue Positioning
8. 9.2.2 Tier 1
9. 9.2.3 Tier 2
10. 9.2.4 Tier 3
11. 9.2.5 Barriers to Entry and Exit
12. 9.3 Key Player Strategies & Positioning
13. 9.3.1 Strategic Group Positioning Narrative
14. 9.3.2 M&A and Partnership Activity Summary (2022–Present)
15. 9.3.3 Differentiation Strategies and Geographic Strongholds
16. 9.3.4 R&D and Technology Investment Trends
17. 9.4 Competitive Dynamics & Strategic Outlook
18. 9.4.1 Emerging Competitive Threats & New Entrant Landscape
19. 9.4.2 Consolidation vs. Fragmentation Outlook
20. 9.4.3 Competitive Response Matrix
21. 9.4.4 Strategic Recommendations for 2025–2031
Porter's Five Forces Analysis
1. 10.1 Threat of New Entrants
2. 10.2 Bargaining Power of Buyers
3. 10.3 Bargaining Power of Suppliers
4. 10.4 Threat of Substitutes
5. 10.5 Competitive Rivalry
PESTLE Analysis
1. 11.1 Overview
2. 11.2 Political
3. Global GLP-1 Drug Manufacturing & Supply Chain Market Strategic Research Report 2026-2031
4. 11.2.1 Reshoring Policy and Manufacturing Nationalism
5. 11.2.2 Geopolitical Fragmentation and Chinese CDMO Risk
6. 11.2.3 Regulatory and Trade Policy Influence on Market Access
7. 11.3 Economic
8. 11.3.1 Extraordinary Capital Investment Intensity
9. 11.3.2 Demand-Supply Mismatch Risk and Pricing Dynamics
10. 11.3.3 CDMO Consolidation Economics
11. 11.4 Sociocultural
12. 11.4.1 The Obesity and Metabolic Disease Burden as Market Foundation
13. 11.4.2 Patient Advocacy and Access Equity Pressure
14. 11.4.3 Workforce and Specialised Talent Dynamics
15. 11.5 Technological
16. 11.5.1 Peptide Synthesis and Biologics Manufacturing Complexity
17. 11.5.2 Delivery Device Technology and Integration Complexity
18. 11.5.3 Digital Supply Chain and Serialisation Technologies
19. 11.5.4 Biosimilar and Generic Entry Technology Dynamics
20. 11.6 Legal
21. 11.6.1 Regulatory Approval Pathways and Market Exclusivity
22. 11.6.2 Biosimilar Regulatory Frameworks and Litigation Risk
23. 11.6.3 Export Controls and Trade Compliance
24. 11.6.4 Quality Regulatory Compliance and GMP Standards
25. 11.7 Environmental
26. 11.7.1 Energy Intensity of Pharmaceutical Manufacturing at Scale
27. 11.7.2 Cold Chain Logistics and Carbon Footprint
28. 11.7.3 Waste Generation and Pharmaceutical Environmental Impact
29. 11.7.4 Site Selection and Environmental Permitting
30. 11.8 PESTLE Summary Assessment
SWOT Analysis
1. 12.1 Executive Overview
2. 12.2 Strengths
3. 12.2.1 Demand Signal of Unprecedented Clarity and Scale
4. 12.2.2 Massive and Accelerating Capital Commitments by Market Leaders
5. 12.2.3 Highly Specialised Technical Barriers to Entry Protecting Incumbents
6. 12.2.4 Established Regulatory Approval Infrastructure at Key Manufacturing Geographies
7. 12.2.5 Integrated Value Chain Depth Creating Cross-Segment Capture Opportunities
8. 12.3 Weaknesses
9. 12.3.1 Severe Concentrated Supply Risk Within a Small Number of Organisations and Sites
10. 12.3.2 Cold Chain and Temperature-Controlled Logistics Infrastructure Gaps
11. 12.3.3 Device Manufacturing Complexity and Component Supply Constraints
12. 12.3.4 Geopolitical Exposure Through WuXi Biologics and Chinese CDMO Dependency
13. 12.3.5 Cross-Report Data Reconciliation Gap Reflecting Market Sizing Uncertainty
14. 12.4 Opportunities
15. 12.4.1 Biosimilar Entry Window Creating Transformative CDMO Demand Through 2026–2031
16. 12.4.2 Asia-Pacific Manufacturing Share Expansion Driven by South Korea and India
17. 12.4.3 Pipeline Expansion Beyond Obesity and Diabetes Into Adjacent Cardiovascular, Renal, and Neurological Indications
18. 12.4.4 Oral GLP-1 Formulations Creating New Formulation and Delivery Manufacturing Segments
19. 12.4.5 Middle East and Africa Strategic Investment as Regional Manufacturing Hubs Emerge
20. 12.4.6 Digital Manufacturing, Continuous Processing, and Process Intensification as Efficiency Multipliers
21. 12.5 Threats
22. 12.5.1 Regulatory and Political Risk From Drug Pricing Legislation and Import Policy
23. 12.5.2 Geopolitical Fragmentation Creating Dual Manufacturing System Requirements
24. 12.5.3 Sustained Capacity Shortfall Damaging Market Trust and Accelerating Biosimilar Entry
25. 12.5.4 Environmental and Solvent Waste Regulatory Tightening Threatening Synthesis Economics
26. 12.5.5 Intellectual Property Litigation Risk Creating Biosimilar Entry Uncertainty
27. Global GLP-1 Drug Manufacturing & Supply Chain Market Strategic Research Report 2026-2031
28. 12.5.6 Data Integrity and Quality System Failures at Scale Creating Regulatory Jeopardy
29. 12.6 Integrated SWOT Assessment and Strategic Implications
Future Trends & Outlook
1. 13.1 Executive Summary of Forward-Looking Dynamics
2. 13.2 Market Scale and Trajectory Through 2031
3. 13.3 Value Chain Evolution: Segment-Level Outlook
4. 13.3.1 API Peptide Synthesis
5. 13.3.2 Drug Product Formulation and Fill-Finish
6. 13.3.3 Delivery Device Manufacturing
7. 13.3.4 Primary Packaging and Containment
8. 13.3.5 Cold Chain and Temperature-Controlled Logistics
9. 13.3.6 Testing, Quality Control, and Regulatory Services
10. 13.4 Regional Outlook and Geographic Competitive Dynamics
11. 13.4.1 North America
12. 13.4.2 Europe
13. 13.4.3 Asia Pacific
14. 13.4.4 Middle East, Africa, and Latin America
15. 13.5 Biosimilar Entry and the Competitive Restructuring of the Supply Chain
16. 13.6 Technology Trends Reshaping Manufacturing Capability
17. 13.6.1 Continuous Manufacturing and Process Intensification
18. 13.6.2 Artificial Intelligence in Quality Control and Supply Chain Management
19. 13.6.3 Oral Formulation Technology
20. 13.7 Supply Chain Resilience and Geopolitical Risk Dimensions
21. 13.7.1 Geographic Concentration Risk
22. 13.7.2 Geopolitical Fragmentation of CDMO Supply Chains
23. 13.7.3 Raw Material and Critical Input Security
24. 13.8 Investment and Capacity Expansion Outlook
25. 13.
Suite Bonus Deliverables
1. Executive Presentation — A 12-slide cross-report visual summary synthesising key findings, market sizes, growth rates, the tirzepatide/semaglutide leadership reversal, and the manufacturing capacity-constraint linkage across both reports.
2. Cross-Report Summary Document — A structured summary explaining how the Manufacturing and Drug Market reports interconnect across the GLP-1 value chain, with a publisher's methodology note.
3. Interactive Infographic — A high-impact visual infographic presenting the key headline data from both markets for executive briefings and stakeholder communication.

Eli Lilly and Company, Novo Nordisk A/S, Biocon Biologics, Amgen Inc., Viking Therapeutics, Zealand Pharma A/S, Hanmi Pharmaceutical Co., Roche / Genentech, Novo Holdings (via Catalent), Samsung Biologics, Lonza, WuXi Biologics

Single User License (PDF)

This license allows for use of a publication by one person.
This person may print out a single copy of the publication.
This person can include information given in the publication in presentations and internal reports by providing full copyright credit to the publisher.
This person cannot share the publication (or any information contained therein) with any other person or persons.
Unless a Enterprise License is purchased, a Single User License must be purchased for every person that wishes to use the publication within the same organization.
Customers who infringe these license terms are liable for a Enterprise license fee.

Site License (PDF)*

This license allows for use of a publication by all users within one corporate location, e.g. a regional office.
These users may print out a single copy of the publication.
These users can include information given in the publication in presentations and internal reports by providing full copyright credit to the publisher.
These users cannot share the publication (or any information contained therein) with any other person or persons outside the corporate location for which the publication is purchased.
Unless a Enterprise License is purchased, a Site User License must be purchased for every corporate location by an organization that wishes to use the publication within the same organization.
Customers who infringe these license terms are liable for a Enterprise license fee.

Enterprise License (PDF)*

This license allows for use of a publication by unlimited users within the purchasing organization e.g. all employees of a single company.
Each of these people may use the publication on any computer, and may print out the report, but may not share the publication (or any information contained therein) with any other person or persons outside of the organization.
These employees of purchasing organization can include information given in the publication in presentations and internal reports by providing full copyright credit to the publisher.

*If Applicable.